Biogen deviates from neuroscience drugs with $800M acquisition

Biogen is expanding its portfolio outside of neuroscience, announcing Monday it is purchasing a British biotech firm focused on retinal disorders for $800 million.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.